ISRCTN83107787已完成1 期
A double-blind, placebo-controlled, single and multiple, dose-escalating, phase I study to assess the safety and tolerability of inhaled interferon-beta (IFN-beta1a) in controlled asthmatic male and female subjects
Synairgen Research Limited (UK)0 个研究点目标入组 40 人开始时间: 2008年2月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •To be eligible for inclusion into this study, each subject must fulfil the following criteria:
- •1. Diagnosis of controlled asthma requiring regular inhaled corticosteroids (ICS). Subjects must have been taking the same dose of ICS regularly for six weeks prior to Screening Visit one.
- •2. Forced expiratory volume in one second (FEV1) is equal to or greater than 80% predicted and diffusing capacity of the lung for carbon monoxide (DLCO/TLCO) equal to or greater than 80% predicted (pre-bronchodilator)
- •3. Presence of bronchial hyperresponsiveness as measured by a methacholine challenge which results in a provocative concentration causing a 20% fall in FEV1 (PC20) equal to or less than 16 mg/ml
- •4. Stable asthma, indicated by asthma symptoms and bronchodilator usage equal to or less than three times a week when needed to relieve symptoms. In addition to this, bronchodilator usage equal to or less than once a day if taken as a preventative prior to exercise will be allowed.
- •5. Male or female aged 18 to 55 years
- •6. Non-smoker or an ex-smoker who has stopped smoking for more than one year and has a smoking history of less than 10 pack-years
- •7. Written informed consent
- •8. Vital signs in the following normal range:
- •8.1. Oral body temperature: 35.0 - 37.5°C
- •8.2. Blood pressure:
- •8.2.1. After at least 3 minutes of rest, measured in the supine position:
- •Systolic blood pressure: 90 - 140 mmHg
- •Diastolic blood pressure: 50 - 90 mmHg
- •8.2.2. Then, after 3 minutes standing:
- •Systolic blood pressure: no more than a 20 mmHg drop
- •Diastolic blood pressure: no more than 10 mmHg drop
- •8.3. Pulse rate: after at least 3 minutes of rest, measured in supine position: 40 - 90 beats per minute (bpm)
- •8.4. Pulse oximetry greater then or equal to 95%
- •9. Motivation to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding the nature of the research and its treatment including its risks and benefits
排除标准
- •Any condition, including findings in the medical history or in the pre-study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for the participation of the subject into the study or that could interfere with the study objectives, conduct or evaluation. In particular:
- •1. Use of long acting bronchodilators
- •2. A change in dose of asthma medication during the past six weeks
- •3. Any clinically significant abnormality in the results of the pre-study safety laboratory tests
- •4. History of any lung disease other than asthma
- •5. Current participation in another clinical trial or participation in a clinical trial where the subject has received a dose of the test product (investigational medicinal product [IMP]) within 12 weeks prior to entry into the study (for small molecules) and within 6 months prior to entry into the study (for biologicals)
- •6. Any clinically significant abnormality on the 12 lead resting electrocardiogram
- •7. History or presence of hypertension or other significant cardiovascular abnormality
- •8. Occurrence of any acute infection or disease within the last six weeks prior to screening
- •9. History of asthma exacerbation and/or upper/lower respiratory tract infection within six weeks prior to screening
- •10. History of hypersensitivity to natural or recombinant interferon-beta or to any of the drug preparation excipients
- •11. History of severe depressive disorders and/or suicidal ideation
- •12. History of liver disease or liver blood test abnormalities other than Gilbert's syndrome
- •13. History of epilepsy or seizures
- •14. Definite or suspected personal history of adverse drug reaction or hypersensitivity to drugs with a similar chemical structure to interferon
- •15. History or presence of drug or alcohol abuse
- •16. Loss or donation of more than 400 ml of blood within 12 weeks prior to entry into the study
- •17. Subjects who have taken any prescription drugs within 6 weeks, other than medication for the treatment of asthma and drugs used for the treatment of atopic dermatitis, atopic rhinitis and other allergic conditions. All other concomitant medications will be at the discretion of the Investigator.
- •18. Subjects who have taken over-the-counter medication, with the exception of multi-vitamins and paracetamol, within 1 week before drug administration. All other concomitant medications will be allowed at the discretion of the Investigator.
- •19. Subjects will undergo training during the screening phase to ensure their ability to use the I-neb® device. If subjects do not show sufficient proficiency in the use of the device, they will not be eligible for inclusion in the study.
- •20. Pregnancy either current or planned over the next 12 weeks. For those who are sexually active precautions are to be advised to both male and female subjects to avoid pregnancy during the trial and follow-up period. These precautions include pregnancy testing at screening, baseline and follow up, as well as the use of a highly effective method of birth control (i.e. the oral contraceptive pill or IUD and the use of condoms) or after surgical sterilisation (i.e. hysterectomy). Continued testing and monitoring will take place during the trial if required.
研究者
相似试验
已完成
不适用
Clinical trial to evaluate the safety and tolerability of CCX507-B in healthy subjectsISRCTN79241600ChemoCentryx, Inc. (USA)30
已完成
不适用
A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX872-B in Healthy Male and Female SubjectsNephropathynierfalen10029149NL-OMON37040Chemocentryx40
已完成
2 期
A double-blind, randomized, placebo-controlled, proof of concept study to investigate the safety and efficacy of the combined administration of 0.5 mg sublingual testosterone and 10 mg tadalafil in women with hypoactive sexual desire disorderproblems with sexual functioning10040480Sexual dysfunctionNL-OMON36064Emotional Brain BV6
进行中（未招募）
不适用
A study on the effect of testosterone and tadalafil on sexual in women with low sexual desireHypoactive Sexual Desire DisorderMedDRA version: 13.1Level: LLTClassification code 10059272Term: Sexual desire decreasedSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 13.1Level: LLTClassification code 10020933Term: Hypoactive sexual desire disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 13.1Level: LLTClassification code 10037228Term: Psychosexual dysfunction with inhibited sexual desireSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 13.1Level: LLTClassification code 10040465Term: Sexual arousal decreasedSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-002770-23-NLEmotional Brain BV
进行中（未招募）
不适用
A study to investigate the subjective and fysiological effects of the combined administration of testosterone and buspirone and buspirone administration alone in women with decreased sexual desireHypoactive Sexual Desire DisorderSexual Interest/Arousal DisorderMedDRA version: 14.1Level: LLTClassification code 10037228Term: Psychosexual dysfunction with inhibited sexual desireSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: LLTClassification code 10059272Term: Sexual desire decreasedSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: LLTClassification code 10040465Term: Sexual arousal decreasedSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: PTClassification code 10058929Term: Disturbance in sexual arousalSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: HLTClassification code 10040470Term: Sexual desire disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: HLTClassification code 10040466Term: Sexual arousal disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: LLTClassification code 10020933Term: Hypoactive sexual desire disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: PTClassification code 10062641Term: Female sexual arousal disorderSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2012-003543-30-NLEmotional Brain BV